Acurx
ACXP
Acurx (ACXP) news
Recent news
Acurx Pharmaceuticals receives FDA conditional acceptance and USPTO trademark allowance for the company's brand name for Ibezapolstat
AInvest Wire · Aug 17, 2026Acurx Pharmaceuticals - FDA open to pre-NDA discussion after single Phase 3 trial if efficacy results are robust
AInvest Wire · Aug 3, 2026Acurx Pharmaceuticals - FDA agrees NDA filing possible for both treatment and recurrence reduction with successful trials
AInvest Wire · Aug 3, 2026Acurx Pharmaceuticals - receives FDA guidance on single Phase 3 trial NDA for Ibezapolstat in CDI
AInvest Wire · Aug 3, 2026Acurx Pharmaceuticals to discuss second quarter 2026 financial results on August 14, 2026 conference call and provide business update
AInvest Wire · Jul 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.